These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 23301767)

  • 41. Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors.
    Lee J; Kim KH; Jeong S
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4203-5. PubMed ID: 21684737
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.
    El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA
    Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis and anticancer activity of some pyrido[2,3-
    Abbas SE; George RF; Samir EM; Aref MM; Abdel-Aziz HA
    Future Med Chem; 2019 Sep; 11(18):2395-2414. PubMed ID: 31544523
    [No Abstract]   [Full Text] [Related]  

  • 44. Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors.
    McIntyre NA; McInnes C; Griffiths G; Barnett AL; Kontopidis G; Slawin AM; Jackson W; Thomas M; Zheleva DI; Wang S; Blake DG; Westwood NJ; Fischer PM
    J Med Chem; 2010 Mar; 53(5):2136-45. PubMed ID: 20146435
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity.
    Abdel-Rahman AA; Shaban AKF; Nassar IF; El-Kady DS; Ismail NSM; Mahmoud SF; Awad HM; El-Sayed WA
    Molecules; 2021 Jun; 26(13):. PubMed ID: 34206976
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.
    Sonawane YA; Taylor MA; Napoleon JV; Rana S; Contreras JI; Natarajan A
    J Med Chem; 2016 Oct; 59(19):8667-8684. PubMed ID: 27171036
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.
    Richardson CM; Williamson DS; Parratt MJ; Borgognoni J; Cansfield AD; Dokurno P; Francis GL; Howes R; Moore JD; Murray JB; Robertson A; Surgenor AE; Torrance CJ
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1353-7. PubMed ID: 16325401
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
    Markwalder JA; Arnone MR; Benfield PA; Boisclair M; Burton CR; Chang CH; Cox SS; Czerniak PM; Dean CL; Doleniak D; Grafstrom R; Harrison BA; Kaltenbach RF; Nugiel DA; Rossi KA; Sherk SR; Sisk LM; Stouten P; Trainor GL; Worland P; Seitz SP
    J Med Chem; 2004 Nov; 47(24):5894-911. PubMed ID: 15537345
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis and Anti-Proliferative Effects of Mono- and Bis-Purinomimetics Targeting Kinases.
    Bistrović A; Harej A; Grbčić P; Sedić M; Kraljević Pavelić S; Cetina M; Raić-Malić S
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29104242
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of novel CDK inhibitors via scaffold hopping from CAN508.
    Jing L; Tang Y; Xiao Z
    Bioorg Med Chem Lett; 2018 May; 28(8):1386-1391. PubMed ID: 29550093
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 2-Anilino-4-(benzimidazol-2-yl)pyrimidines--a multikinase inhibitor scaffold with antiproliferative activity toward cancer cell lines.
    Determann R; Dreher J; Baumann K; Preu L; Jones PG; Totzke F; Schächtele C; Kubbutat MH; Kunick C
    Eur J Med Chem; 2012 Jul; 53():254-63. PubMed ID: 22560627
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery and SAR studies of novel 2-anilinopyrimidine-based selective inhibitors against triple-negative breast cancer cell line MDA-MB-468.
    Jo J; Kim SH; Kim H; Jeong M; Kwak JH; Taek Han Y; Jeong JY; Jung YS; Yun H
    Bioorg Med Chem Lett; 2019 Jan; 29(1):62-65. PubMed ID: 30447889
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis, Docking Studies into CDK-2 and Anticancer Activity of New Derivatives Based Pyrimidine Scaffold and Their Derived Glycosides.
    Rahman AAHA; Nassar IF; Shaban AKF; El-Kady DS; Awad HM; El Sayed WA
    Mini Rev Med Chem; 2019; 19(13):1093-1110. PubMed ID: 30864522
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement.
    Barlaam B; De Savi C; Dishington A; Drew L; Ferguson AD; Ferguson D; Gu C; Hande S; Hassall L; Hawkins J; Hird AW; Holmes J; Lamb ML; Lister AS; McGuire TM; Moore JE; O'Connell N; Patel A; Pike KG; Sarkar U; Shao W; Stead D; Varnes JG; Vasbinder MM; Wang L; Wu L; Xue L; Yang B; Yao T
    J Med Chem; 2021 Oct; 64(20):15189-15213. PubMed ID: 34647738
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy.
    Alsfouk A
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):693-706. PubMed ID: 33632038
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.
    Wang Y; Liu WJ; Yin L; Li H; Chen ZH; Zhu DX; Song XQ; Cheng ZZ; Song P; Wang Z; Li ZG
    Bioorg Med Chem Lett; 2018 Mar; 28(5):974-978. PubMed ID: 29429832
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition.
    Han Y; Tian Y; Wang R; Fu S; Jiang J; Dong J; Qin M; Hou Y; Zhao Y
    Bioorg Chem; 2020 Nov; 104():104197. PubMed ID: 32927132
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
    Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors.
    Lawrence HR; Martin MP; Luo Y; Pireddu R; Yang H; Gevariya H; Ozcan S; Zhu JY; Kendig R; Rodriguez M; Elias R; Cheng JQ; Sebti SM; Schonbrunn E; Lawrence NJ
    J Med Chem; 2012 Sep; 55(17):7392-7416. PubMed ID: 22803810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.